Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.50 |
| ▸ | HTR6 | P50406 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 9/20 | 0.46 |
| ▸ | HTR7 | P34969 | 9/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582493 | 0.97 | KCNH2 (0.52) | KCNH2HTR6HTR1AHTR7SLC6A4 | |
| SCHEMBL6582403 | 0.95 | KCNH2 (0.50) | KCNH2HTR6HTR1AHTR7SLC6A4 | |
| SCHEMBL6581206 | 0.90 | KCNH2 (0.53) | KCNH2HTR6HTR1AHTR7SLC6A4 | |
| SCHEMBL6586131 | 0.88 | KCNH2 (0.51) | KCNH2HTR6HTR1AHTR7SLC6A4 | |
| SCHEMBL6580436 | 0.87 | KCNH2 (0.66) | KCNH2HTR6HTR1AHTR7SLC6A4 | |
| SCHEMBL6584644 | 0.84 | KCNH2 (0.63) | KCNH2HTR6HTR1AHTR7SLC6A4 | |
| SCHEMBL6585806 | 0.83 | KCNH2 (0.57) | KCNH2HTR6HTR1AHTR7SLC6A4 | |
| SCHEMBL6582650 | 0.83 | KCNH2 (0.53) | KCNH2HTR6HTR1AHTR7SLC6A4 | |
| SCHEMBL6584408 | 0.81 | KCNH2 (0.66) | KCNH2HTR6HTR1AHTR7SLC6A4 | |
| SCHEMBL6591500 | 0.81 | HTR1A (0.70) | KCNH2HTR6HTR1AHTR7SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246815-B1 | PHENYLPIPERAZINYL DERIVATIVES | LUNDBECK & CO AS H (DK) | 2004-03-17 | — | — | EP | disclosed |
| US-20030083336-A1 | Phenylpiperazinyl derivatives | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| EP-1246819-A1 | A METHOD FOR THE PREPARATION OF SUBSTITUTED BENZENE DERIVATIVES | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049681-A1 | A METHOD FOR THE PREPARATION OF SUBSTITUTED BENZENE DERIVATIVES | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083336-A1 | Phenylpiperazinyl derivatives | DRD4, DRD2, DRD3 | KCNH2 341/4885HTR6 72/4885HTR1A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.